Windtree Offloads Cardiovascular Pipeline for Upfront Cash, Contingent Payments, and a Royalty Stake

summarizeSummary

Windtree sold its cardiovascular drug candidates to Seismic Pharmaceutical Operations for $150,000 upfront, a potential $700,000 contingent payment, and 20% of future proceeds, while transferring development payables to the buyer.

check_boxKey Events · M&A and Partnerships · WINT

• Cardiovascular Assets Sold

  Windtree sold its cardiovascular drug candidates to Seismic Pharmaceutical Operations, LLC for $150,000 upfront, a $700,000 contingent payment if the buyer raises $10M+, and 20% of future milestone, royalty, or commercial revenue.

• Financial Impact

  Upfront cash of $150,000 is significant relative to Windtree's sub-$500K market cap; the contingent $700,000 payment and 20% royalty provide non-dilutive upside without further development costs.

• Liability Transfer

  Certain cardiovascular development payables were transferred to the buyer, reducing Windtree's obligations and cash burn.

• Delayed Disclosure

  The agreement was signed December 16, 2025, but the 8-K was filed July 21, 2026 — a seven-month gap that raises governance questions.

auto_awesomeAnalysis · WINT · Life Sciences

Windtree sold its cardiovascular drug candidates to Seismic Pharmaceutical Operations, LLC, receiving $150,000 upfront, a potential $700,000 if the buyer raises at least $10 million, and 20% of any future milestone, royalty, or commercial revenue. The deal also transfers certain development payables to the buyer, removing funding obligations from Windtree. For a micro-cap company with a market cap under $500,000, this transaction provides non-dilutive cash and a royalty stake in a multi-billion-dollar acute heart failure market, while offloading liabilities. The 8-K was filed in July 2026 but reports an agreement signed in December 2025 — the delayed disclosure itself is a governance concern, but the deal terms are material and previously undisclosed.